Du Kim - PanGen Biotech Internal Auditor

222110 Stock  KRW 6,000  290.00  4.61%   

Insider

Du Kim is Internal Auditor of PanGen Biotech
Age 64
Phone82 3 1733 9165
Webhttp://www.pangen.com

PanGen Biotech Management Efficiency

The company has return on total asset (ROA) of (0.079) % which means that it has lost $0.079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (24.8877) %, meaning that it generated substantial loss on money invested by shareholders. PanGen Biotech's management efficiency ratios could be used to measure how well PanGen Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
PanGen Biotech has accumulated 5.49 M in total debt with debt to equity ratio (D/E) of 1.52, which is about average as compared to similar companies. PanGen Biotech has a current ratio of 1.1, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist PanGen Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, PanGen Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PanGen Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PanGen to invest in growth at high rates of return. When we think about PanGen Biotech's use of debt, we should always consider it together with cash and equity.
PanGen Biotech Inc. operates as a specialized biologics company in South Korea. The company was founded in 1999 and is based in Suwon, South Korea. PanGen is traded on Korean Securities Dealers Automated Quotations in South Korea. PanGen Biotech (222110) is traded on KOSDAQ in Korea and employs 7 people.

Management Performance

PanGen Biotech Leadership Team

Elected by the shareholders, the PanGen Biotech's board of directors comprises two types of representatives: PanGen Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PanGen. The board's role is to monitor PanGen Biotech's management team and ensure that shareholders' interests are well served. PanGen Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PanGen Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jae Jang, Chief Executive Officer, Director, Assistant Managing Director
Tae Byun, Chief Operating Officer, Vice President
Ji Kim, Assistant Managing Director
Jaeseung Yoon, Co-Chief Executive Officer, Director
Du Kim, Internal Auditor
Gwang Park, Director
Yeong Kim, Co-Chief Executive Officer, Director

PanGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PanGen Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with PanGen Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PanGen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PanGen Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against PanGen Stock

  0.87123040 MS Autotech CoLtdPairCorr
  0.87101400 N CitronPairCorr
  0.87122690 Seojin Automotive CoLtdPairCorr
  0.84012700 LEADCORPPairCorr
  0.84027710 FarmStoryPairCorr
The ability to find closely correlated positions to PanGen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PanGen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PanGen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PanGen Biotech to buy it.
The correlation of PanGen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PanGen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PanGen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PanGen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in PanGen Stock

PanGen Biotech financial ratios help investors to determine whether PanGen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PanGen with respect to the benefits of owning PanGen Biotech security.